Cargando…

Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome

Atrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin r...

Descripción completa

Detalles Bibliográficos
Autores principales: Itani, Hana A., Jaffa, Miran A., Elias, Joseph, Sabra, Mohammad, Zakka, Patrick, Ballout, Jad, Bekdash, Amira, Ibrahim, Rand, Al Hariri, Moustafa, Ghemrawi, Mirna, Abi-Saleh, Bernard, Khoury, Maurice, Alam, Samir, Mahfouz, Rami, Jaffa, Ayad A., Azar, Sami T., Refaat, Marwan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738559/
https://www.ncbi.nlm.nih.gov/pubmed/33344519
http://dx.doi.org/10.3389/fcvm.2020.613271
_version_ 1783623143006404608
author Itani, Hana A.
Jaffa, Miran A.
Elias, Joseph
Sabra, Mohammad
Zakka, Patrick
Ballout, Jad
Bekdash, Amira
Ibrahim, Rand
Al Hariri, Moustafa
Ghemrawi, Mirna
Abi-Saleh, Bernard
Khoury, Maurice
Alam, Samir
Mahfouz, Rami
Jaffa, Ayad A.
Azar, Sami T.
Refaat, Marwan M.
author_facet Itani, Hana A.
Jaffa, Miran A.
Elias, Joseph
Sabra, Mohammad
Zakka, Patrick
Ballout, Jad
Bekdash, Amira
Ibrahim, Rand
Al Hariri, Moustafa
Ghemrawi, Mirna
Abi-Saleh, Bernard
Khoury, Maurice
Alam, Samir
Mahfouz, Rami
Jaffa, Ayad A.
Azar, Sami T.
Refaat, Marwan M.
author_sort Itani, Hana A.
collection PubMed
description Atrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin resistance/glucose intolerance are also associated with inflammation and increased level of cytokines and adipokines. We hypothesized that the inflammatory immune response is exacerbated in patients with both AF and CMS compared to either AF or CMS alone. We investigated inflammatory cytokines and fibrotic markers as well as cytokine genetic profiles in patients with lone AF and CMS. CMS, lone AF patients, patients with both lone AF and CMS, and control patients were recruited. Genetic polymorphisms in inflammatory and fibrotic markers were assessed. Serum levels of connective tissue growth factor (CTGF) were tested along with other inflammatory markers including platelet-to-lymphocyte ratio (PLR), monocyte-to-HDL ratio (MHR) in three groups of AF+CMS, AF, and CMS patients. There was a trend in the CTGF levels for statistical significance between the AF and AF+CMS group (P = 0.084). Genotyping showed high percentages of patients in all groups with high secretor genotypes of Interleukin-6 (IL-6) (P = 0.037). Genotyping of IFN-γ and IL-10 at high level showed an increase in expression in the AF + CMS group compared to AF and CMS alone suggesting an imbalance between the inflammatory and anti-inflammatory cytokines which is exacerbated by AF. Serum cytokine inflammatory cytokine levels showed that IL-4, IL-5, IL-10, IL-17F, and IL-22 were significant between the AF, AF+CMS, and CMS patients. Combination of both CMS and AF may be associated with a higher degree of inflammation than what is seen in either CMS or AF alone. Thus, the identification of a biomarker capable of identifying metabolic syndrome associated with disease will help in identification of a therapeutic target in treating this devastating disease.
format Online
Article
Text
id pubmed-7738559
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77385592020-12-17 Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome Itani, Hana A. Jaffa, Miran A. Elias, Joseph Sabra, Mohammad Zakka, Patrick Ballout, Jad Bekdash, Amira Ibrahim, Rand Al Hariri, Moustafa Ghemrawi, Mirna Abi-Saleh, Bernard Khoury, Maurice Alam, Samir Mahfouz, Rami Jaffa, Ayad A. Azar, Sami T. Refaat, Marwan M. Front Cardiovasc Med Cardiovascular Medicine Atrial fibrillation (AF) and cardiometabolic syndrome (CMS) have been linked to inflammation and fibrosis. However, it is still unknown which inflammatory cytokines contribute to the pathogenesis of AF. Furthermore, cardiometabolic syndrome (CMS) risk factors such as obesity, hypertension, insulin resistance/glucose intolerance are also associated with inflammation and increased level of cytokines and adipokines. We hypothesized that the inflammatory immune response is exacerbated in patients with both AF and CMS compared to either AF or CMS alone. We investigated inflammatory cytokines and fibrotic markers as well as cytokine genetic profiles in patients with lone AF and CMS. CMS, lone AF patients, patients with both lone AF and CMS, and control patients were recruited. Genetic polymorphisms in inflammatory and fibrotic markers were assessed. Serum levels of connective tissue growth factor (CTGF) were tested along with other inflammatory markers including platelet-to-lymphocyte ratio (PLR), monocyte-to-HDL ratio (MHR) in three groups of AF+CMS, AF, and CMS patients. There was a trend in the CTGF levels for statistical significance between the AF and AF+CMS group (P = 0.084). Genotyping showed high percentages of patients in all groups with high secretor genotypes of Interleukin-6 (IL-6) (P = 0.037). Genotyping of IFN-γ and IL-10 at high level showed an increase in expression in the AF + CMS group compared to AF and CMS alone suggesting an imbalance between the inflammatory and anti-inflammatory cytokines which is exacerbated by AF. Serum cytokine inflammatory cytokine levels showed that IL-4, IL-5, IL-10, IL-17F, and IL-22 were significant between the AF, AF+CMS, and CMS patients. Combination of both CMS and AF may be associated with a higher degree of inflammation than what is seen in either CMS or AF alone. Thus, the identification of a biomarker capable of identifying metabolic syndrome associated with disease will help in identification of a therapeutic target in treating this devastating disease. Frontiers Media S.A. 2020-12-02 /pmc/articles/PMC7738559/ /pubmed/33344519 http://dx.doi.org/10.3389/fcvm.2020.613271 Text en Copyright © 2020 Itani, Jaffa, Elias, Sabra, Zakka, Ballout, Bekdash, Ibrahim, Al Hariri, Ghemrawi, Abi-Saleh, Khoury, Alam, Mahfouz, Jaffa, Azar and Refaat. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Itani, Hana A.
Jaffa, Miran A.
Elias, Joseph
Sabra, Mohammad
Zakka, Patrick
Ballout, Jad
Bekdash, Amira
Ibrahim, Rand
Al Hariri, Moustafa
Ghemrawi, Mirna
Abi-Saleh, Bernard
Khoury, Maurice
Alam, Samir
Mahfouz, Rami
Jaffa, Ayad A.
Azar, Sami T.
Refaat, Marwan M.
Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome
title Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome
title_full Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome
title_fullStr Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome
title_full_unstemmed Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome
title_short Genomic and Proteomic Study of the Inflammatory Pathway in Patients With Atrial Fibrillation and Cardiometabolic Syndrome
title_sort genomic and proteomic study of the inflammatory pathway in patients with atrial fibrillation and cardiometabolic syndrome
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738559/
https://www.ncbi.nlm.nih.gov/pubmed/33344519
http://dx.doi.org/10.3389/fcvm.2020.613271
work_keys_str_mv AT itanihanaa genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT jaffamirana genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT eliasjoseph genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT sabramohammad genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT zakkapatrick genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT balloutjad genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT bekdashamira genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT ibrahimrand genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT alharirimoustafa genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT ghemrawimirna genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT abisalehbernard genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT khourymaurice genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT alamsamir genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT mahfouzrami genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT jaffaayada genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT azarsamit genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome
AT refaatmarwanm genomicandproteomicstudyoftheinflammatorypathwayinpatientswithatrialfibrillationandcardiometabolicsyndrome